Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia
Authors
Tekalign, SAdera, C
den Boer, M
Miecha, H
Zewde, A
Mulugeta, D
Bishawu, T
Birru, W
Lema, A
Sahlu, T
Alves, F
Manzi, M
Takarinda, K
Van Griensven, J
Issue Date
2020-06-30Submitted date
2020-07-25
Metadata
Show full item recordAbstract
Introduction: In three health care facilities in the Oromia region, the aim of this study is to report on 1) the number of VL cases registered over time (2013-2018) and 2) the clinical profile, type of treatment used and response to treatment. Methodology: A retrospective cohort study was conducted among all VL cases admitted with a diagnosis of VL. Results: A total of 434 VL cases were registered at the three health facilities, but patient files were available for only 188. Most (51.6%) were children and only three presented with VL relapse. 78 (41.5%) of the 188 patients presented within one month of symptom onset. Concurrent severe acute malnutrition (27.1%), tuberculosis (6.4%) and malaria (6.4%) were common. There were only two cases with HIV coinfection. Fourty-three percent were treated with antimonials, 34% with antimonials combined with paromomycin and 23% with AmBisome. Amongst the 188 patients with patient files there were no deaths and one treatment failure. Six months outcome data were however missing for all. Aggregated data from the 434 VL cases reported three deaths, two treatment failures and one relapse. Conclusions: Children were most commonly affected, suggesting long-term endemicity. While short-term outcomes are encouraging, long-term follow-up data are required.PubMed ID
32614795Type
ArticleLanguage
enEISSN
1972-2680ae974a485f413a2113503eed53cd6c53
10.3855/jidc.11731
Scopus Count
Collections
Related articles
- The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
- Authors: Abongomera C, Diro E, de Lima Pereira A, Buyze J, Stille K, Ahmed F, van Griensven J, Ritmeijer K
- Issue date: 2018 May
- Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
- Authors: Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, Sanz MG, Sunyoto T, Kumar S, Mitra G, Kumar R, Verma N, Das P
- Issue date: 2014 Aug
- Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
- Authors: Salih NA, van Griensven J, Chappuis F, Antierens A, Mumina A, Hammam O, Boulle P, Alirol E, Alnour M, Elhag MS, Manzi M, Kizito W, Zachariah R
- Issue date: 2014 Feb
- Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
- Authors: Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN
- Issue date: 2011 Dec
- Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia.
- Authors: Welay GM, Alene KA, Dachew BA
- Issue date: 2016